Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Nov 9:7:F1000 Faculty Rev-1772.
doi: 10.12688/f1000research.15903.1. eCollection 2018.

Recent advances in managing brain metastasis

Rupesh Kotecha  1   2 , Vinai Gondi  3   4 , Manmeet S Ahluwalia  5   6 , Priscilla K Brastianos  7   8 , Minesh P Mehta  1   2
Affiliations
Review

Recent advances in managing brain metastasis

Rupesh Kotecha et al. F1000Res. .

Abstract

Brain metastases are the most common malignancy encountered in the central nervous system (CNS), with up to 30-40% of cancer patients developing brain metastases at some point during the course of their disease. The management of brain metastasis is rapidly evolving and the roles of local therapies such as whole-brain radiation therapy, stereotactic radiosurgery, and resection along with systemic therapies are in flux. An emphasis on the neurocognitive side effects associated with treatment has gained prominence. Novel molecular studies have demonstrated important evolutionary patterns underpinning the development of brain metastasis and leptomeningeal disease, which may be key to unlocking new therapeutic strategies. This article provides a framework for incorporating the results of recent randomized radiotherapy clinical trials into practice, expounds upon the emphasis on cognition being an important driver in therapeutic selection, describes the importance of CNS-penetrating systemic therapies, and provides an overview of the novel molecular insights that will likely set the stage for future developments in this field.

Keywords: brain metastasis; genomic; neurocognition; stereotactic radiosurgery; targeted therapy; whole brain radiation therapy.

PubMed Disclaimer

Conflict of interest statement

No competing interests were disclosed.No competing interests were disclosed.No competing interests were disclosed.

References

    1. Horton J, Baxter DH, Olson KB: The management of metastases to the brain by irradiation and corticosteroids. Am J Roentgenol Radium Ther Nucl Med. 1971;111(2):334–6. 10.2214/ajr.111.2.334 - DOI - PubMed
    1. Mulvenna P, Nankivell M, Barton R, et al. : Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): Results from a phase 3, non-inferiority, randomised trial. Lancet. 2016;388(10055):2004–14. 10.1016/S0140-6736(16)30825-X - DOI - PMC - PubMed

    2. F1000 Recommendation

    1. Patchell RA, Tibbs PA, Regine WF, et al. : Postoperative radiotherapy in the treatment of single metastases to the brain: A randomized trial. JAMA. 1998;280(17):1485–9. 10.1001/jama.280.17.1485 - DOI - PubMed
    1. Mahajan A, Ahmed S, McAleer MF, et al. : Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: A single-centre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18(8):1040–8. 10.1016/S1470-2045(17)30414-X - DOI - PMC - PubMed

    2. F1000 Recommendation

    1. Soliman H, Ruschin M, Angelov L, et al. : Consensus Contouring Guidelines for Postoperative Completely Resected Cavity Stereotactic Radiosurgery for Brain Metastases. Int J Radiat Oncol Biol Phys. 2018;100(2):436–42. 10.1016/j.ijrobp.2017.09.047 - DOI - PubMed

    2. F1000 Recommendation